tiprankstipranks
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
PremiumPress ReleasesSCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
3M ago
Scynexis announces presentation of data from fungerp candidate SCY-247
PremiumThe Fly
Scynexis announces presentation of data from fungerp candidate SCY-247
3M ago
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
PremiumPress Releases
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
3M ago
SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
PremiumPress ReleasesSCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
5M ago
Scynexis files $200M mixed securities shelf
PremiumThe Fly
Scynexis files $200M mixed securities shelf
5M ago
Scynexis files to sell 32.52M shares of common stock
PremiumThe Fly
Scynexis files to sell 32.52M shares of common stock
5M ago
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance
PremiumPress ReleasesSCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance
7M ago
Scynexis down 29% after announcing Brexafemme recall
PremiumThe Fly
Scynexis down 29% after announcing Brexafemme recall
7M ago
Scynexis recalling Brexafemme from market, placing temporary hold on studies
PremiumThe Fly
Scynexis recalling Brexafemme from market, placing temporary hold on studies
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100